APA (7th ed.) Citation

Rodler, E., Sharma, P., Barlow, W. E., Gralow, J. R., Puhalla, S. L., Anders, C. K., . . . Hayes, D. F. (2023). Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, 24(2), 162. https://doi.org/10.1016/S1470-2045(22)00739-2

Chicago Style (17th ed.) Citation

Rodler, Eve, et al. "Cisplatin with Veliparib or Placebo in Metastatic Triple-negative Breast Cancer and BRCA Mutation-associated Breast Cancer (S1416): A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." Lancet Oncology 24, no. 2 (2023): 162. https://doi.org/10.1016/S1470-2045(22)00739-2.

MLA (9th ed.) Citation

Rodler, Eve, et al. "Cisplatin with Veliparib or Placebo in Metastatic Triple-negative Breast Cancer and BRCA Mutation-associated Breast Cancer (S1416): A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." Lancet Oncology, vol. 24, no. 2, 2023, p. 162, https://doi.org/10.1016/S1470-2045(22)00739-2.